216 related articles for article (PubMed ID: 37435231)
1.
Gao C; Chang L; Xu T; Li X; Chen Z
J Gastrointest Oncol; 2023 Jun; 14(3):1412-1433. PubMed ID: 37435231
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-128-3p Mediates Lenvatinib Resistance of Hepatocellular Carcinoma Cells by Downregulating c-Met.
Xu X; Jiang W; Han P; Zhang J; Tong L; Sun X
J Hepatocell Carcinoma; 2022; 9():113-126. PubMed ID: 35252056
[TBL] [Abstract][Full Text] [Related]
3. Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression.
Zhao Z; Zhang D; Wu F; Tu J; Song J; Xu M; Ji J
J Cell Mol Med; 2021 Jan; 25(1):549-560. PubMed ID: 33210432
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of the lncRNA HOTAIRM1 promotes lenvatinib resistance by downregulating miR-34a and activating autophagy in hepatocellular carcinoma.
Gu D; Tong M; Wang J; Zhang B; Liu J; Song G; Zhu B
Discov Oncol; 2023 May; 14(1):66. PubMed ID: 37171645
[TBL] [Abstract][Full Text] [Related]
5. Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma.
Sun D; Liu J; Wang Y; Dong J
Front Oncol; 2022; 12():944537. PubMed ID: 36158676
[TBL] [Abstract][Full Text] [Related]
6. [The regulation of APGAT4 on the growth and lenvatinib resistance of hepatocellular carcinoma].
Li Z; Yang NH; Li B; Sun CY
Zhonghua Gan Zang Bing Za Zhi; 2023 Apr; 31(4):408-414. PubMed ID: 37248980
[No Abstract] [Full Text] [Related]
7. METTL3-m
Wang L; Yang Q; Zhou Q; Fang F; Lei K; Liu Z; Zheng G; Zhu L; Huo J; Li X; Peng S; Kuang M; Lin S; Huang M; Xu L
Cancer Lett; 2023 Apr; 559():216122. PubMed ID: 36898427
[TBL] [Abstract][Full Text] [Related]
8. TRIM52 up-regulation in hepatocellular carcinoma cells promotes proliferation, migration and invasion through the ubiquitination of PPM1A.
Zhang Y; Tao R; Wu SS; Xu CC; Wang JL; Chen J; Yu YS; Tang ZH; Chen XH; Zang GQ
J Exp Clin Cancer Res; 2018 Jun; 37(1):116. PubMed ID: 29898761
[TBL] [Abstract][Full Text] [Related]
9. ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
Myojin Y; Kodama T; Maesaka K; Motooka D; Sato Y; Tanaka S; Abe Y; Ohkawa K; Mita E; Hayashi Y; Hikita H; Sakamori R; Tatsumi T; Taguchi A; Eguchi H; Takehara T
Clin Cancer Res; 2021 Feb; 27(4):1150-1161. PubMed ID: 33288659
[TBL] [Abstract][Full Text] [Related]
10. Exosomal MiR-744 Inhibits Proliferation and Sorafenib Chemoresistance in Hepatocellular Carcinoma by Targeting PAX2.
Wang G; Zhao W; Wang H; Qiu G; Jiang Z; Wei G; Li X
Med Sci Monit; 2019 Sep; 25():7209-7217. PubMed ID: 31553714
[TBL] [Abstract][Full Text] [Related]
11. N6-Methyladenosine-Mediated Up-Regulation of FZD10 Regulates Liver Cancer Stem Cells' Properties and Lenvatinib Resistance Through WNT/β-Catenin and Hippo Signaling Pathways.
Wang J; Yu H; Dong W; Zhang C; Hu M; Ma W; Jiang X; Li H; Yang P; Xiang D
Gastroenterology; 2023 May; 164(6):990-1005. PubMed ID: 36764493
[TBL] [Abstract][Full Text] [Related]
12. Hsa-microRNA-27b-3p inhibits hepatocellular carcinoma progression by inactivating transforming growth factor-activated kinase-binding protein 3/nuclear factor kappa B signalling.
Wen J; Huang Z; Wei Y; Xue L; Wang Y; Liao J; Liang J; Chen X; Chu L; Zhang B
Cell Mol Biol Lett; 2022 Sep; 27(1):79. PubMed ID: 36138344
[TBL] [Abstract][Full Text] [Related]
13. Effect of Lenvatinib treatment on the cell cycle and microRNA profile in hepatocellular carcinoma cells.
Nakahara M; Fujihara S; Iwama H; Takuma K; Oura K; Tadokoro T; Fujita K; Tani J; Morishita A; Kobara H; Himoto T; Masaki T
Biomed Rep; 2022 Oct; 17(4):78. PubMed ID: 36158319
[TBL] [Abstract][Full Text] [Related]
14. EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells.
He X; Hikiba Y; Suzuki Y; Nakamori Y; Kanemaru Y; Sugimori M; Sato T; Nozaki A; Chuma M; Maeda S
Sci Rep; 2022 May; 12(1):8007. PubMed ID: 35568782
[TBL] [Abstract][Full Text] [Related]
15. CircPAK1 promotes the progression of hepatocellular carcinoma via modulation of YAP nucleus localization by interacting with 14-3-3ζ.
Hao X; Zhang Y; Shi X; Liu H; Zheng Z; Han G; Rong D; Zhang C; Tang W; Wang X
J Exp Clin Cancer Res; 2022 Sep; 41(1):281. PubMed ID: 36131287
[TBL] [Abstract][Full Text] [Related]
16. Aberrant expression of two miRNAs promotes proliferation, hepatitis B virus amplification, migration and invasion of hepatocellular carcinoma cells: evidence from bioinformatic analysis and experimental validation.
Liu Y; Cao Y; Cai W; Wu L; Zhao P; Liu XG
PeerJ; 2020; 8():e9100. PubMed ID: 32377460
[TBL] [Abstract][Full Text] [Related]
17. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells.
Li W; Dong X; He C; Tan G; Li Z; Zhai B; Feng J; Jiang X; Liu C; Jiang H; Sun X
J Exp Clin Cancer Res; 2019 May; 38(1):183. PubMed ID: 31053148
[TBL] [Abstract][Full Text] [Related]
18. FOXA2 plays a critical role in hepatocellular carcinoma progression and lenvatinib-associated drug resistance.
Wang Z; Shen J; Chen C; Wen T; Li C
Biosci Trends; 2023 May; 17(2):136-147. PubMed ID: 36823043
[TBL] [Abstract][Full Text] [Related]
19. Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma.
Miyazaki K; Morine Y; Xu C; Nakasu C; Wada Y; Teraoku H; Yamada S; Saito Y; Ikemoto T; Shimada M; Goel A
Cells; 2023 Feb; 12(4):. PubMed ID: 36831279
[TBL] [Abstract][Full Text] [Related]
20. Effect of gigantol on the proliferation of hepatocellular carcinoma cells tested by a network-based pharmacological approach and experiments.
Li S; Li H; Yin D; Xue X; Chen X; Li X; Li J; Yi Y
Front Biosci (Landmark Ed); 2022 Jan; 27(1):25. PubMed ID: 35090330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
